This doctor has experience in endocrine treatment, collaborating on studies aimed at overcoming resistance to hormone therapy. They have also been involved in numerous phase 1, 2 and 3 studies in breast and melanoma, which have led to the approval of new drugs in new indications. Their main area of interest lies in immunotherapy for melanoma treatment and patient care. They have participated in trials that have led to the approval of cdk4/6 palbociclib and ribociclib inhibitors in the first line of metastatic breast cancer, and Pembrolizumab in the first line of metastatic melanoma, as well as the combination of Nivolumab and Ipilimumab. They are a member of the Breast Cancer Unit and Melanoma Unit at the Vall d'Hebron University Hospital and the Vall d'Hebron Institute of Oncology. This doctor is an experienced oncologist with expertise in breast cancer and melanoma treatments, including endocrine therapy, immunotherapy, and patient care. They have been involved in numerous clinical trials leading to the approval of new drugs in new indications.
Read moreThis doctor has experience in endocrine treatment, collaborating on studies aimed at overcoming resistance to hormone therapy. They have also been involved in numerous phase 1, 2 and 3 studies in breast and melanoma, which have led to the approval of new drugs in new indications. Their main area of interest lies in immunotherapy for melanoma treatment and patient care. They have participated in trials that have led to the approval of cdk4/6 palbociclib and ribociclib inhibitors in the first line of metastatic breast cancer, and Pembrolizumab in the first line of metastatic melanoma, as well as the combination of Nivolumab and Ipilimumab. They are a member of the Breast Cancer Unit and Melanoma Unit at the Vall d'Hebron University Hospital and the Vall d'Hebron Institute of Oncology. This doctor is an experienced oncologist with expertise in breast cancer and melanoma treatments, including endocrine therapy, immunotherapy, and patient care. They have been involved in numerous clinical trials leading to the approval of new drugs in new indications.
Bookimed, a leading global medical tourism platform, is committed to helping clients looking for Topical therapy of melanoma by offering expert assistance and trustworthy medical solutions for every situation. Smart automatic ranking system is used to compose transparent clinic listings, meticulously maintained by a data scientist using AI for accuracy. The platform guarantees authenticity by publishing reviews from real patients after their treatments. Bookimed offers comprehensive medical solutions, with updates from clinics to ensure trustworthiness. The content about Topical therapy of melanoma, crafted by experienced medical authors and reviewed by specialists, adheres to Bookimed"s Editorial Guidelines, reflecting the platform"s commitment to delivering high-quality and clear health information. For more details or inquiries, feel free to contact us at marketing@bookimed.com or learn more about us and our mission here.
Doctor Yesim Yildirim is an oncologist certified by the European Society of Medical Oncology (ESMO). Affiliated with numerous hospitals in the United States and Turkey, including the University of Maryland Medical Center, Johns Hopkins Hospital and Memorial Sisli Hospital. She has over 20 years of experience and has a special interest in preventive medicine, diabetes, and hypertension. Holds an MBA in Healthcare Management and shares her expertise with Bookimed from 2022.
The Medical Advisory Board expert is a verified credible medical professional with solid theoretical background and practical experience in the field. The expert provides support related to medical content accuracy for medical writers and performs educational workshops to Bookimed coordinators serving patient requests.
The medical content creation under the expert’s control follows rigorous and well-established procedure to be informative, trustworthy, and transparent and making Bookimed.com a credible source of evidence-based health information.